News
[MUSIC PLAYING] Chemotherapy is a very broad term used to describe agents that go into the veins through an IV to treat prostate cancer that has spread to other parts of the body. These medicines ...
1h
Investor's Business Daily on MSNAstraZeneca Tops Earnings Views And Shares Rise Despite Cancer MissAstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.Earnings beat expectations by 10%, Leerink Partners analyst ...
Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.
AstraZeneca has discontinued its CAPItello-280 phase three trial assessing Truqap, or capivasertib, in combination with docetaxel and androgen-deprivation therapy (ADT) for patients with metastatic ...
Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming ... during or after docetaxel-based chemotherapy. Two agents (cabazitaxel and ...
chemotherapy-induced menopause) or hormonal treatments, such as tamoxifen or aromatase inhibitors for breast cancer or androgen ablation for prostate cancer. The effects of chemotherapy-associated ...
A newly expanded prostate cancer ... that is given before chemotherapy. (RLTs are a form of targeted nuclear medicine that doctors use to treat multiple types of cancer, according to Novartis.) ...
Lenny Santoro credits NIH research with saving his life longer than doctors expected. Duke Health's Dr. Daniel George warns ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on ...
Prostate cancer remains one of the most ... which reduces levels of male hormones that can accelerate cancer growth, and chemotherapy, which employs powerful medications to kill rapidly dividing ...
More debate about whether the lowest-risk prostate cancers should ... KRAS G12C-mutated metastatic colorectal cancer after specific chemotherapy regimens. The agency also approved acalabrutinib ...
The UK regulator has said eligible patients with prostate cancer will get early ... after three or more prior anti-androgen and chemotherapy regimens. "With over 11,500 prostate cancer deaths ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results